HISUN(SH:600267) Zhong Zheng Wang·2025-10-30 12:06Core Viewpoint - The collaboration between Haizheng Pharmaceutical and Shengzhao Pharmaceuticals marks a significant step in the development of a joint venture focused on complex injectable drugs, aiming to enhance innovation and internationalization in the pharmaceutical industry [1][2][3] Group 1: Joint Venture Details - Haizheng Pharmaceutical and Shengzhao Pharmaceuticals have established a joint venture in Taizhou, Zhejiang, focusing on complex injectable drugs [2] - Haizheng Pharmaceutical will invest 495 million yuan for a 45% stake, while Shengzhao Pharmaceuticals will invest 605 million yuan for a 55% stake [2] - The joint venture will develop, produce, and commercialize 11 complex injectable products, including generic drugs and modified new drugs [2] Group 2: Strategic Importance - The partnership is a crucial step for Haizheng Pharmaceutical in advancing its international development strategy, aligning with the industry's focus on high-quality and innovative drug development [2] - The collaboration aims to enhance the capabilities in research, production, and global commercialization of complex injectables, facilitating alignment with international standards [2][3] - The joint venture is expected to provide better treatment options in critical areas such as cancer, CNS disorders, and pain management, contributing to the upgrade of China's pharmaceutical industry [2]